PMV Pharmaceuticals Inc (PMVP)
2.10
-0.05
(-2.33%)
USD |
NASDAQ |
May 17, 16:00
2.10
0.00 (0.00%)
After-Hours: 20:00
PMV Pharmaceuticals Enterprise Value: -89.91M for May 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 17, 2024 | -89.91M |
| May 16, 2024 | -87.34M |
| May 15, 2024 | -86.82M |
| May 14, 2024 | -87.85M |
| May 13, 2024 | -88.36M |
| May 10, 2024 | -92.99M |
| May 09, 2024 | -89.91M |
| May 08, 2024 | -86.82M |
| May 07, 2024 | -85.79M |
| May 06, 2024 | -89.91M |
| May 03, 2024 | -95.57M |
| May 02, 2024 | -101.74M |
| May 01, 2024 | -102.25M |
| April 30, 2024 | -105.34M |
| April 29, 2024 | -106.88M |
| April 26, 2024 | -107.91M |
| April 25, 2024 | -109.97M |
| April 24, 2024 | -111.00M |
| April 23, 2024 | -105.08M |
| April 22, 2024 | -108.94M |
| April 19, 2024 | -115.12M |
| April 18, 2024 | -114.60M |
| April 17, 2024 | -115.12M |
| April 16, 2024 | -115.63M |
| April 15, 2024 | -113.83M |
| Date | Value |
|---|---|
| April 12, 2024 | -105.86M |
| April 11, 2024 | -116.66M |
| April 10, 2024 | -120.26M |
| April 09, 2024 | -116.66M |
| April 08, 2024 | -117.69M |
| April 05, 2024 | -115.63M |
| April 04, 2024 | -115.63M |
| April 03, 2024 | -110.48M |
| April 02, 2024 | -105.85M |
| April 01, 2024 | -106.37M |
| March 28, 2024 | -115.60M |
| March 27, 2024 | -118.18M |
| March 26, 2024 | -117.66M |
| March 25, 2024 | -115.60M |
| March 22, 2024 | -116.12M |
| March 21, 2024 | -114.57M |
| March 20, 2024 | -117.15M |
| March 19, 2024 | -116.12M |
| March 18, 2024 | -117.15M |
| March 15, 2024 | -112.52M |
| March 14, 2024 | -118.18M |
| March 13, 2024 | -120.75M |
| March 12, 2024 | -118.18M |
| March 11, 2024 | -119.20M |
| March 08, 2024 | -115.60M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-138.99M
Minimum
Oct 25 2023
2.393B
Maximum
Dec 31 2020
512.59M
Average
348.21M
Median
Jun 03 2022
Enterprise Value Benchmarks
| Exelixis Inc | 5.128B |
| Geron Corp | 1.900B |
| Verastem Inc | 243.31M |
| Karyopharm Therapeutics Inc | 157.92M |
| Kura Oncology Inc | 1.171B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -15.27M |
| Total Expenses (Quarterly) | 18.22M |
| EPS Diluted (Quarterly) | -0.30 |
| Earnings Yield | -63.33% |